Glucose stimulates human beta cell replication in vivo in islets transplanted into NOD-severe combined immunodeficiency (SCID) mice.

Division of Endocrinology and Metabolism, University of Pittsburgh School of Medicine, 200 Lothrop St, BST E1140, Pittsburgh, PA 15261, USA.
Diabetologia (Impact Factor: 6.88). 10/2010; 54(3):572-82. DOI: 10.1007/s00125-010-1919-1
Source: PubMed

ABSTRACT We determined whether hyperglycaemia stimulates human beta cell replication in vivo in an islet transplant model
Human islets were transplanted into streptozotocin-induced diabetic NOD-severe combined immunodeficiency mice. Blood glucose was measured serially during a 2 week graft revascularisation period. Engrafted mice were then catheterised in the femoral artery and vein, and infused intravenously with BrdU for 4 days to label replicating beta cells. Mice with restored normoglycaemia were co-infused with either 0.9% (wt/vol.) saline or 50% (wt/vol.) glucose to generate glycaemic differences among grafts from the same donors. During infusions, blood glucose was measured daily. After infusion, human beta cell replication and apoptosis were measured in graft sections using immunofluorescence for insulin, and BrdU or TUNEL.
Human islet grafts corrected diabetes in the majority of cases. Among grafts from the same donor, human beta cell proliferation doubled in those exposed to higher glucose relative to lower glucose. Across the entire cohort of grafts, higher blood glucose was strongly correlated with increased beta cell replication. Beta cell replication rates were unrelated to circulating human insulin levels or donor age, but tended to correlate with donor BMI. Beta cell TUNEL reactivity was not measurably increased in grafts exposed to elevated blood glucose.
Glucose is a mitogenic stimulus for transplanted human beta cells in vivo. Investigating the underlying pathways may point to mechanisms capable of expanding human beta cell mass in vivo.


Available from: Laura C Alonso, Apr 16, 2015
  • [Show abstract] [Hide abstract]
    ABSTRACT: Strategies that simultaneously enhance the survival and glucose responsiveness of insulin-producing β cells will greatly augment β cell replacement therapies in type 1 diabetes (T1D). We show that genetic and pharmacologic mimetics of the phosphorylated BCL-2 homology 3 (BH3) domain of BAD impart β-cell-autonomous protective effects in the face of stress stimuli relevant to β cell demise in T1D. Importantly, these benefits translate into improved engraftment of donor islets in transplanted diabetic mice, increased β cell viability in islet grafts, restoration of insulin release, and diabetes reversal. Survival of β cells in this setting is not merely due to the inability of phospho-BAD to suppress prosurvival BCL-2 proteins but requires its activation of the glucose-metabolizing enzyme glucokinase. Thus, BAD phospho-BH3 mimetics may prove useful in the restoration of functional β cell mass in diabetes. Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cure of type 1 diabetes (T1D) by immune intervention at disease onset depends on the restoration of insulin secretion by endogenous beta cells. However, little is known about the potential of beta cell mass and function to recover after autoimmune attack ablation. Utilizing a longitudinal in vivo imaging approach we here show how functional status and mass of beta cells adapt in response to onset and remission of T1D. We demonstrate that infiltration reduces beta cell mass prior to diabetes and, together with emerging hyperglycemia, affects beta cell function. After immune intervention persisting hyperglycemia prevents functional recovery, but promotes beta cell mass increase in mouse islets. When blood glucose levels return to normoglycemia beta cell mass expansion stops and subsequently glucose tolerance recovers in combination with beta cell function. Similar to mouse, human islets exhibit cell exhaustion and recovery in response to transient hyperglycemia. However, the effect of hyperglycemia on human islet mass increase is minor and transient. Our data demonstrate a major role of functional exhaustion and recovery of beta cells during diabetes onset and remission. Therefore, these findings support early intervention therapy of diabetes. © 2015 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered.
    Diabetes 01/2015; DOI:10.2337/db14-1055 · 8.47 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Context Neural crest stem cells (NCSCs) are capable of substantially improving murine islet function by promoting β-cell proliferation. Objective: The present study aimed to investigate the potential of NCSCs to stimulate human β-cell proliferation, and improve neural and vascular engraftment of human islets. Design, setting, and subjects Human pancreatic islets from 15 brain-dead cadaveric donors (age range 19-78 years) were obtained through the Nordic Network for Clinical Islet Transplantation. β-cell proliferation and graft function was investigated at our experimental laboratory. Intervention and main outcome measures Human islets were transplanted, either alone or together with spheres of NCSCs. β-cell proliferation, as well as islet neural and vascular densities, were assessed by immunohistochemistry. Graft blood perfusion and oxygen tension were measured using laser-Doppler flowmetry and Clark microelectrodes, respectively. Results: Two days posttransplantation, the number of Ki67 positive β-cells was doubled in human islets that had been exposed to NCSCs. Similar findings were obtained in vitro, as well as with EdU as proliferation marker. Four weeks posttransplantation, NCSC-exposed human islet grafts had much higher neural and vascular densities. The newly formed blood vessels were also functional, since these human islets had a substantially higher blood perfusion and oxygen tension when compared to control transplants. Conclusion: We conclude that exposure to NCSCs stimulates human β-cell proliferation, and that these cells improve both the neural and vascular engraftment of transplanted human islets. NCSCs are a promising cellular therapy for translation into clinical use.
    Journal of Clinical Endocrinology &amp Metabolism 02/2015; DOI:10.1210/jc.2014-4070 · 6.31 Impact Factor